YOLT 102
Alternative Names: YOLT-102Latest Information Update: 16 Jan 2024
At a glance
- Originator YolTech Therapeutics
- Class Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 25 Oct 2023 Early research in Metabolic disorders in China (Parenteral), prior to October 2023 (YolTech Therapeutics pipeline, October 2023)